U S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

TRANMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER	U S APPLICATION NO. (If known, see 37 CFR 1 5)
PALTIELI=1	09/937706

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY CLAIMED
PCT/IL00/00196	29 March 2000	30 March 1999

TITLE OF INVENTION
ANTIBODIES TO PLACENTAL PROTEIN 13

APPLICANT(S) FOR DO/EO/US
Yoav PALTIELI et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. [X] This is a **FIRST** submission of items concerning a filing under 35 U S.C. 371.
2. [ ] This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. [X] This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. [X] The US has been elected in a Demand by the expiration of 19 months from the priority date (PCT Article 31).
5. [X] A copy of the International Application as filed (35 U.S.C. 371(c)(2))
   a. [ ] is attached hereto (required only if not transmitted by the International Bureau).
   b. [X] has been communicated by the International Bureau.
   c. [ ] is not required, as the application was filed in the United States Receiving Office (RO/US).
6. [ ] An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
7. [X] Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
   a. [ ] are transmitted herewith (required only if not transmitted by the International Bureau).
   b. [ ] have been communicated by the International Bureau.
   c. [ ] have not been made; however, the time limit for making such amendments has NOT expired.
   d. [X] have not been made and will not be made.
8. [ ] An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. [ ] An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. [ ] An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. [ ] An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. [ ] An Assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. [X] A FIRST preliminary amendment.
    [ ] A SECOND or SUBSEQUENT preliminary amendment.
14. [ ] A substitute specification.
15. [ ] A change of power of attorney and/or address letter.
16. [X] Other items or information:
    [X] Courtesy copy of the International Application as filed.
    [X] Courtesy copy of the first page of the International Publication (WO 00/58364).
    [X] Courtesy copy of the International Preliminary Examination Report. Annexes are attached but are not to be used for initial examination in this case.]
    [X] Formal drawings, 18 sheets, Figures 1-15.
    [X] Courtesy Copy of the International Search Report.
    [X] Application Data Sheet
    [X] The application is (or will be) assigned to: DIAGNOSTIC TECHNOLOGIES LTD., whose address is Beit Etgarim, Etar Street 4, 39120 Tirat HaCarmel, Israel.

U.S. APPLICATION NO (If known, see 37 CFR 1 5)	International Application No	Attorney's Docket No
09/937706	PCT/IL00/00196	PALTIELI=1

17. [xx] The following fees are submitted:	CALCULATIONS PTO USE ONLY
BASIC NATIONAL FEE (37 CFR 1.492 (a)(1) –(5):	
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1 445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO.....**$1040.00**	
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO..... ....**$890.00**	
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO..... .....**$740.00**	
International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4)..... ...**$710.00**	
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4)..... .....**$100.00**	

ENTER APPROPRIATE BASIC FEE AMOUNT =				$ 890.00	
Surcharge of **$130.00** for furnishing the oath or declaration later than [ ] 20 [X] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				$ 130.00	
Claims as Originally Presented	Number Filed	Number Extra	Rate		
Total Claims	15 - 20		X $18.00	$	
Independent Claims	2 - 3		X $84.00	$	
Multiple Dependent Claims (if applicable)			+$280.00	$ 280.00	
TOTAL OF ABOVE CALCULATIONS =				$1,300.00	
Claims After Post Filing Prel. Amend	Number Filed	Number Extra	Rate		
Total Claims	- 20		X $18.00	$	
Independent Claims	- 3		X $84.00	$	
TOTAL OF ABOVE CALCULATIONS =				$1,300.00	
Reduction of ½ for filing by small entity, if applicable. Applicant claims small entity status. See 37 CFR 1.27.				$	
SUBTOTAL =				$1,300.00	
Processing fee of **$130.00** for furnishing the English translation later than [ ]20 [ ]30 months from the earliest claimed priority date (37 CFR 1.492(f)).				$	
TOTAL NATIONAL FEE =				$1,300.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). **$40.00** per property +				$	
TOTAL FEES ENCLOSED =				$1,300.00	
				Amount to be: refunded	$
				charged	$

a. [ ] A check in the amount of $_____ to cover the above fees is enclosed.
b. [X] Credit Card Payment Form (PTO-2038), authorizing payment in the amount of $ 1,300.00, is attached.
c. [ ] Please charge my Deposit Account No. **02-4035** in the amount of $_____ to cover the above fees. A duplicate copy of this sheet is enclosed.
d. [**XX**] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **02-4035**. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

BROWDY AND NEIMARK, P.L.L.C.
624 NINTH STREET, N.W., SUITE 300
WASHINGTON, D.C. 20001
TEL: (202) 628-5197
FAX: (202) 737-3528

SIGNATURE
Sheridan Neimark
NAME
20,520
REGISTRATION NUMBER

Date of this submission: **October 1, 2001**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Yoav PALTIELI et al.	)	Art Unit:
IA No.: PCT/IL00/00196	)	Washington, D.C.
IA Filed: 29 March 2000	)	
U.S. App. No.: (Not Yet Assigned)	)	October 1, 2001
National Filing Date: (Not Yet Received)	)	
For: ANTIBODIES TO PLACENTAL…	)	Docket No.: PALTIELI=1

PRELIMINARY AMENDMENT

Honorable Commissioner for Patents and Trademarks
Washington, D.C. 20231

Sir:

Contemporaneous with the filing of this case and prior to calculation of the filing fee, kindly amend as follows:

IN THE SPECIFICATION

After the title please insert the following paragraph:

--**REFERENCE TO RELATED APPLICATIONS**

The present application is the national stage under 35 U.S.C. 371 of international application PCT/IL00/00196, filed 29 March 2000 which designated the United States, and which international application was published under PCT Article 21(2) in the English language.-- SN

In re of: Yoav PALTIELI et al. (PALTIELI=1)

REMARKS

The above amendment to the specification is being made to insert reference to the PCT application of which the present case is a U.S. national stage.

Favorable consideration is earnestly solicited.

Respectfully submitted,
BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant

By: _____
Sheridan Neimark
Registration No. 20,520

SN:wrd
Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528

18/prts

ANTIBODIES TO PLACENTAL PROTEIN 13

FIELD OF THE INVENTION

This invention relates to antibodies raised against a placental protein.

BACKGROUND OF THE INVENTION

References referred to in the text by a number enclosed by parenthesis are listed at the end of the specification.

The goal of pregnancy management is the delivery of a mature, healthy infant, without encountering complications which can adversely affect the well being of both the mother and the newborn. A significant percentage of pregnancies are affected by various disorders. Among them are preterm delivery, intrauterine growth retardation and preeclampsia. These complications negatively impact the outcome of affected pregnancies, at enormous cost both to the patients as well as to the health system.

Placental Protein 13 (PP13) is a protein which was previously isolated from human placental tissue (U.S. 4.500,451 to Bohn, *et al.*, the contents of which are incorporated herein by reference). The protein was characterized by the following parameters: electrophoretic mobility, isoelectric point, sedimentation coefficient, molecular weight determined by ultracentrifugation, molecular weight determined by SDS-PAGE electrophoresis, extinction coefficient and carbohydrate content. The amino acid composition (residues per 100 residues) was determined but not the amino acid sequence.

PP13 was used to develop an assay for the early stage detection of three specific pregnancy-related disorders: intrauterine growth retardation, preeclampsia and preterm delivery (U.S. 5.198.366 to Silberman, the contents of which are incorporated herein by reference). Both a radioimmunoassay (RIA) and an enzyme-linked immunosorbent assay (ELISA) were developed using labeled PP13 and anti PP13 polyclonal antiserum. respectively. However. experimental results were given only for the RIA. and not for the ELISA. No further properties of PP13 are disclosed in the Silberman patent. There have also been reports in the literature regarding the determination of other placental proteins and their relationship to pregnancy disorders (1-3).

The ELISA fulfils requirements of objectivity. simplicity, sensitivity and specificity previously only attained by radioimmunoassay (4). A methodological comparison of ELISA and RIA reveals several advantages of the former method:

1. ELISA is absolutely safe and does not require a specially designed laboratory and trained personnel for working with radioactive material.

2. Two-antibody sandwich ELISA is a more sensitive. rapid and easily quantitatable method.

3. Enzymes are rather stable as compared with radioactive tracers and cause a high level of result reproducibility.

4. The enzymatic activity may be measured easily using the spectrophotometric principle of an ELISA-reader. which is much cheaper and simpler in handling than a gamma-counter.

5. ELISA is more suitable for automation.

It is therefore desirable to develop an improved ELISA for the determination of PP13 levels.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide monoclonal antibodies (Mab) capable of binding PP13.

It is a further object of the invention to provide an immunoassay which measures the level of PP13 in biological fluids.

In one aspect of the invention, there is provided a Mab capable of binding PP13. In particular, the invention provides hybridoma clones selected from the group consisting of clones # 26-2, 27-2-3, 215-28-3, 534-16 and 606-8-11-67, as well as the Mab produced by these clones. These clones have been deposited in accordance with the Budapest Treaty at the Collection Nationale de Cultures de Microorganismes of the Pasteur Institute of 25, Rue du Docteur Roux, Paris, France. The following are the depository details of the clones:

Clone #	Accession No.	Deposit Date
26-2	I-2134	March 4, 1999
27-2-3	I-2135	March 4, 1999
215-28-3	I-2136	March 4, 1999
534-16	I-2137	March 4, 1999
606-8-11-67	I-2138	March 4, 1999

In another aspect of the invention, there is provided an immunoassay for measuring the level of PP-13 in a biological fluid comprising the steps of: (a) bringing the fluid into contact with a Mab according to the invention, thereby forming Mab-PP-13 complexes: (b) exposing the complexes to a second antibody linked to a signal-generating molecule, the second antibody being capable of binding the complexes; and (c) providing conditions conducive to the production of a signal generated by the signal-generating molecule.

In the present specification, the term *"signal-generating molecule"* relates to a molecule capable of generating, either directly or indirectly, a detectable signal. The signal may be, e.g. a radioactive emission or a spectrophotometric absorbance at a specific wavelength. Preferably, the signal will be a color which can be detected by a spectrophotometric reader. The signal-generating molecule may generate the signal directly, e.g. by reacting itself with a chromogenic substrate, or indirectly, e.g. by binding to another molecule which is able to generate a signal. In a preferred embodiment, the signal-generating molecule is a ligand which generates a signal indirectly by binding to a ligand-binding molecule which is linked to an enzyme, which in turn catalyzes a reaction resulting in color formation.

The biological fluid may be any fluid which may contain PP13, such as placental extract or blood serum. Preferably, the fluid is blood serum. In one embodiment of this aspect of the invention, the Mab, which binds one site on PP13, is bound to a solid phase such as a microtiter well or a bead. The second antibody will be capable of binding another site on PP13, and may be polyclonal or monoclonal. In a preferred embodiment, the second antibody is also a Mab according to the invention.

In a further aspect of the invention, there is provided a kit for measuring the level of PP-13 in a biological fluid comprising: (a) a Mab according to the invention; (b) a second antibody linked to a signal-generating molecule; and (c) PP-13 standard solutions. In a preferred embodiment, the second antibody is also a Mab, as described above. The kit may be used to carry out an immunoassay as described above.

BRIEF DESCRIPTION OF THE DRAWINGS:

In order to understand the invention and to see how it may be carried out in practice, a preferred embodiment will now be described, by way of

non-limiting example only, with reference to the accompanying drawings, in which:

Fig. 1 shows a SDS-PAGE electrophoresis of mouse anti-PP-13 ascites & IgG (the gel is overloaded for visualization of impurities);

Fig. 2 illustrates testing of mouse anti-PP-13 serum in a direct ELISA:

Fig. 3 illustrates classing of anti-PP-13 antibodies in a direct ELISA;

Figs. 4 & 5 illustrate testing of anti-PP-13 antibodies in a sandwich ELISA:

Figs. 6-9 illustrate classing of anti-PP-13 antibodies in a direct ELISA (cloning: 2nd screening);

Fig. 10 illustrates classing of anti-PP-13 antibodies in a direct ELISA (cloning: 3rd screening);

Fig. 11 illustrates a two-monoclonal antibody sandwich ELISA in different variants;

Fig. 12 shows a standard curve of PP-13 ELISA (monoclonal sandwich):

Fig. 13 illustrates sensitivity of PP-13 ELISA (monoclonal sandwich):

Fig. 14 illustrates a dilution curve of PP-13 in the blood serum (monoclonal sandwich ELISA); and

Fig. 15 illustrates an analytical recovery test of PP-13 (monoclonal sandwich ELISA).

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

MATERIALS AND METHODS

(a) Purification of PP-13

PP-13 used in this study was isolated and purified from human

placenta according to the method described by Bohn *et al.* with some modifications. Freshly obtained placenta was stripped of membranes and the maternal outer layer. The inner fetal trophoblast region was chopped into small pieces and homogenized in a blender with about 1.5 liters of DDW for 5 min. All subsequent steps were carried out at 4°C. The pH of the extract was adjusted to 7.0 by adding several drops of concentrated NaOH. The extract was then rehomogenized with a tissue homogenizer (Politron) for 5 min. in batches of 300 ml. The homogenized placental extract was stirred for 30 min. and then centrifuged for 60 min. at 10.000 rpm (Sorval large rotor). The supernatant was saved. supplemented with 0.5M NaCl. 100 mM Tris-HCl, 0.05% Tween 20 and 0.1% NaN_3. and filtered through depth filters. using a vacuum pump. The filtrate containing PP-13 was collected for the first immunoabsorbance column and stored at -20°C.

A 60 ml bed volume anti-PP-13 immunoabsorbance column (I), containing rabbit anti-PP-13 IgG fraction was equilibrated with buffer A (1M NaCl. 100 mM Tris-HCl, 0.1% NaN_3. pH 8.0). This column was sufficient to handle the extract of one placenta. The placental extract was loaded onto the column at a flow rate of 4 ml/min. The column was washed with buffer A until the optical density (OD) level reached the baseline. The PP-13 peak was eluted from the column with a 6 M urea solution (treated with 1 mg/10 ml of amberlite ionic exchanger MB-6, 20-50 mesh). The eluted protein solution (about 150 ml) was concentrated by ultrafiltration, using 10 kD MW cut-off disk membranes, to a final volume of 50 ml. At the same time, the buffer was switched to phosphate buffer saline (PBS). containing 0.1% NaN_3. pH 7.4.

A 60 ml bed volume anti-placental extract negative immunoabsorbance column (II), containing rabbit anti-human placental extract IgG fraction was equilibrated with PBS + 0.1% NaN_3, pH 7.4. PP-13 enriched extract obtained from column I was loaded onto the column at a

flow rate of 3 ml/min. The unbound protein (about 130 ml) was collected and concentrated using 10 kD MW cut-off disk membranes to a final volume of 40 ml. The column was regenerated with 6M urea solution to remove impurities bound to the column and washed with 5 bed volumes of PBS + 0.1% sodium azide.

A 56 ml bed volume anti-human globulin negative immunoabsorbance column (III), containing rabbit anti- human alfa-1, beta- and delta-globulins IgG was equilibrated with PBS. The PP-13 concentrated extract obtained from the column II was loaded onto the column III at a flow rate of 3 ml/min. Unbound protein (about 120 ml) was collected and the column was regenerated with 6M urea solution and washed with PBS. This material was repurified using the first immunoabsorbance column, and then used for gel-filtration chromatography which was performed on a Superdex 75 Hiload 26/60 column. The concentrated PP-13 fraction (about 3 ml) was loaded onto the gel-filtration column equilibrated previously with PBS at a flow rate of 3 ml/min. The column was washed with PBS and fractions of 5 ml each were collected. PP-13 was eluted as a third peak, concentrated to a volume of 1 ml. analyzed for purity by SDS-PAGE electrophoresis (5) and quantitated by the Microbradford method and by ELISA.

(b) Development of anti-PP-13 monoclonal antibodies

Monoclonal anti-PP-13 antibodies (Mab) were produced in the Weizmann Institute (Israel). Five three-month old female Balb/c mice (Jackson) were immunized twice with 0.05 mg PP-13 in PBS and complete Freund's adjuvant per injection per mouse (i.d. and s.c.). and twice with PP-13 in PBS without adjuvant. The injections were made into each of the hind-footpads and afterwards at multiple sites at both the sides and back of the mice. The injections were separated by an interval of two weeks. Test

bleeds were carried out 10 days after the third and fourth immunizations.

Three weeks later, two mice having the best response (see results section) received two injections of 0.05 mg PP-13 i.p. during two consecutive days. Five days after the last boost, spleens of those two mice were removed and 100 million cells from each individual spleen were fused using 41% polyethylene glycol 1500 (Serva, Heidelberg, FRG) with 20 million NSO/1 myeloma line cells kindly provided by C. Milstein (MRC, Cambridge, UK), as described previously (6).

Following fusion, cells were distributed into six microplates (96 wells each) at a concentration of 50.000 viable cells/well. Hybrid cells selected for growth in the presence of HAT were kept in a humidified incubator in the presence of 8% CO_2 in air. The growth medium was Dulbecco's modified Eagle's medium (DMEM high glucose, Gibco) supplemented with 1 mM pyruvate, 2 mM glutamine, penicillin (10 units/ml), streptomycin (0.02 mg/ml) and 15% heat inactivated horse serum (HS, Beit Haemek Biological Industries, Israel). Positive hybrid cultures were weaned out of HAT, cloned by limiting dilution, recloned in soft agar and propagated *in vitro* in large volumes of DMEM-HS or *in vivo* as ascites in pyrstane-treated (BALB/c x DBA/2) mice.

Ascitic fluids produced using the best clones were affinity purified on a protein G column (Sigma, Cat. # P 4691). IgG fractions were collected, dialyzed, concentrated, quantitated and tested in an antibody-capture direct ELISA. Aliquots were biotinylated and tested again in an antibody-capture direct ELISA and in variants of a two-monoclonal Ab sandwich ELISA. The best combination of antibodies with the highest sensitivity was chosen for development of a two-monoclonal Ab sandwich ELISA.

Antibody-capture direct ELISA was employed for the screening of anti- PP-13 antibodies. Microtiter plates were coated with purified PP-13 and blocked with 1% BSA in PBS. Antisera of test bleeds, hybridoma

culture supernatants or ascitic fluids were applied as a primary antibody. Normal mouse serum (NMS) served as a negative control. AP-goat anti-mouse IgG (Fc) without cross-reactivity with other mouse immunoglobulins (Sigma. Cat. # A 1418) and Biotin-goat anti-mouse IgM (Zymed Laboratories. Inc.. Cat. # 62-6840) were used as the secondary antibodies for determination of antibody class specificity. AP-Extravidin was applied to the microplate wells previously incubated with biotinylated Ab.

After incubation with the substrate. optical density was detected in a Microplate-reader (BIO-TEK Instruments. Inc.) at 405 nm. Since the affinity of the Ab is closely related to the sensitivity of an assay, monoclonal Ab affinities and ability to work with another Ab as a pair were evaluated using two-antibody sandwich ELISA with rabbit polyclonal anti-PP-13 IgG as a primary Ab. Purified PP-13 served as a standard solution with concentrations from 0 to 2.0 ng/ ml. Antisera of test bleeds, hybridoma culture supernatants or ascitic fluids were applied as the secondary antibodies. AP-goat anti-mouse IgG was used as detecting Ab. After incubation with the substrate. ELISA plates were scanned in the Microplate- reader at 405 nm.

(c) Two-monoclonal antibody sandwich ELISA

A two-monoclonal antibody sandwich solid-phase enzyme immunoassay with biotin-extravidin amplification system was established for PP-13 measurement in biological fluids. Highly purified PP-13 from human placenta was used as a standard and control. Two IgG fractions of purified ascitic fluids showed the best result in the two-antibody sandwich assay test used for ELISA development. The level of their purity was controlled by SDS-PAGE electrophoresis (Fig. 1). One Ab was used for coating of flat bottom 96-well Nunc-microplates while the second served as

a secondary antibody after biotinylation.

ELISA plates were coated with anti-PP-13 IgG in PBS and incubated for 2 hours at room temperature. After incubation the plates were washed 3 times with PBS + 0.05% Tween 20 and blocked with assay buffer (PBS + 1% BSA + 0.05% Tween 20) for 2 hours at room temperature. Afterwards the plates were washed in the same manner. PP-13 standard and controls diluted in pooled male serum/assay buffer (1:3) or unknown specimen (blood serum) diluted in assay buffer (1:3) were loaded and microplates were incubated overnight at room temperature. After this and all the following steps the plates were washed 3 times with assay buffer. Biotin-anti-PP-13 IgG in assay buffer as a secondary Ab was added and the plates were incubated for 2 hours at room temperature. Then ELISA plates were incubated with extravidin- alkaline phosphatase solution (Sigma, Cat. # E 2636) in assay buffer for 2 hours at room temperature. The reaction was developed by adding substrate- chromogen mixture (Sigma, Cat. # 104-105) and the results were detected by an ELISA reader at 405 nm. The amount of standard or unknown antigen was determined as an optical density (OD) of the sample minus blank (pooled male serum/assay buffer, 1:3). A standard curve was established by plotting this data against the known amount of PP-13. 2SD confidence interval of standard curve has been plotted as a basis for the quality control statistics. Results were calculated using Dbase software.

RESULTS

(a) Testing of anti-PP-13 monoclonal antibodies

(i) Test bleeds

Blood sera obtained from five immunized mice during test bleeds were titered (1:200 – 1:48600) to monitor the development of the response. Blood samples were checked in antibody capture direct ELISA. Mice # 1, 2,

4 were found to have a strong response: high levels of specific Ab were detected. Titers of antisera from mice # 3 and # 5 were lower (Fig. 2). The same mice showed quite high antibody affinities in sandwich ELISA recognizing different concentrations of PP-13 starting from 50 pg/ml (not shown). Two mice. # 1 and # 2 having the best response. were chosen for the last boost and fusion.

(ii) Screening of tissue culture supernatnats (sups)

Tissue culture sups were screened periodically during hybridoma growing by antibody capture ELISA using AP-goat anti-mouse IgG. Positive samples were rescreened using the same secondary Ab and Biotin-goat anti- mouse IgM for identifying the class of Ab. Sups # 12, 26, 27. 59. 79, 140, 215, 249. 409, 442. 489, 502. 531. 534, 606, 669, 676, 808, 882 were rescreened. It was found. that Ab # 26. 27, 215. 249, 534, 606, 669. 882 belonged to IgG class, Ab # 12. 59. 79. 489, 502. 531, 676 were classified as IgM and Ab # 140, 409. 442. 808 showed low levels with both secondary Abs (selected results are shown in Fig. 3).

The Ab affinities were evaluated in sandwich ELISA with rabbit anti-PP-13 IgG as a primary Ab. Tissue cultures # 27. 215 and 534 produced Ab with high affinity (selected results are shown in Fig. 4). Tissue cultures # 26. 27, 215. 249. 534, 606. 669. 882 producing Ab of IgG class were chosen for cloning. Their clones were rescreened in the same manner (Figs. 5-10). Taking into consideration the class. level and affinity of Ab, the most stable clones # 26-2, 27-2-3. 215-28-3. 534-16, 606-8-11-67 were used for the induction of ascites:

Clone # 26-2 produced Ab of IgG class with a high level of response.

Clone # 27-2-3 produced Ab of IgG class with high affinity; the detection limit was 0.05 ng/ml of PP-13.

Clone # 215-28-3 produced Ab of IgG class with relatively high response and best affinity, recognizing different concentrations of PP-13

starting from 0.05 ng/ml.

Clone # 534-16 produced Ab of IgG class with relatively high affinity: the detection limit of PP-13 concentration was 0.2 ng/ml.

Clone # 606-8-11-67 produced Ab of IgG class with a high level of response.

(iii) Purifying and testing ascitic fluids

Five ascites # 26-2, 27-2-3, 215-28-3, 534-16, 606-8-11-67 were affinity purified on a protein G column (Sigma, Cat. # P 4691). Their IgG fractions were tested in the Ab capture direct ELISA confirming IgG class. Aliquots of these Ab were biotinylated. After labeling, biotin-Ab were checked in the Ab capture direct ELISA, using AP-Extravidin as detecting reagent. All the Abs recognized PP-13 after biotinylation. Two- antibody sandwich assays with different combinations of primary and secondary Ab were carried out. The most effective variant was found to use IgG # 27-2-3 for coating and Biotin-IgG # 215-28-3 as a secondary Ab (Fig. 11). The sensitivity of this assay was 0.05 ng/ml of PP-13.

(b) Characterization of two-antibody sandwich ELISA

(i) Standard curve statistics

Assay conditions of a two-antibody sandwich ELISA were optimized and a standard curve was constructed. Different concentrations of PP-13 were used: 10, 20, 50, 100, 200, 500 pg/ml (Fig. 12). Optical densities of P-13 standard samples minus blank vs. known amount of PP-13 were plotted. An effective range of from 10 to 500 pg/ml PP-13 concentrations was reliably measured. The standard curve shape was nearly linear; the correlation coefficient between PP-13 concentrations and optical densities was $r = 0.99$. The SD of residuals from the line = 0.08, p value < 0.0001 (two tailed). Its slope was quite steep, with a y-axis intercept near 0.

Averaged coefficient of variation of standard curve data points was 5.6%, and 2SD confidence limits were rather narrow.

(ii) Sensitivity of the test

This parameter is defined as the minimal detection limit of an assay which is to be determined as the least concentration of PP-13 which can be distinguished from a sample containing no protein. The distinction is based on the confidence limits of the estimate of the zero standard on the one hand. and the standard on the other. It is seen from the graph (Fig. 13) that 10 pg/ml of PP-13 could be clearly distinguished from zero. This is the maximum sensitivity which can be attained using the sandwich ELISA technique.

(iii) Specificity

The traditional method for detecting any type of non-specificity is an examination of parallelism between dilutions of specimen and standard. A high level of parallelism has been found between pooled blood serum samples and different concentrations of standard PP-13 solution in dilution experiment. Series of pooled serum dilutions has been made: 1:2. 1:4, 1:8 and 1:16. Normalized data points of blood serum and standard PP-13 solution were plotted (Fig. 14). Correlation between two dilution curves was calculated. The slope of pooled serum curve was = 1.02; correlation coefficient r = 0.9998; SD of residuals from the line = 2.79; p value < 0.0001 (two tailed).

(iv) Analytical recovery test

This test is based on determination of known concentrations of PP-13 in a blood serum. Pooled blood serum from pregnant women was supplemented with four known amounts of PP-13: 20, 50, 100 and 200 pg/ml and analyzed together with the same concentrations of PP-13 control

pool. The data points were plotted on a graph (Fig. 15). The overall analytical recovery was found to be 106.2% and the curve was linear with the slope = 1.03. Correlation between estimated PP-13 levels in pooled blood serum and in the control pool was very strong (r = 1).

(v)Intra- and inter-assay variation

These parameters were used for evaluation of an assay precision. Intra-assay variation was assessed as the coefficient of variation of control samples estimated within the same assay and calculated as:

CV(%) = Standard deviation/mean*100%.

It was found to be between 1.5% and 3.5%. Inter-assay variation was calculated according to the same formula, based on estimations of aliquots from the quality-control pool in every assay run and was found to be between 2.6% and 8.4% (Table 1).

Table 1 – Intra- and Inter-assay Variation of PP-13 ELISA

PP-13 level pg/ml	Intra-assay variation (CV, %) (n = 16 each)	Inter-assay variation (CV, %) (n = 8 assays)
20	1.54	4.61
50	3.51	8.39
100	2.01	4.64
200	1.91	2.56

(c) PP-13 levels in human blood serum

Two-monoclonal antibody sandwich ELISA was employed for PP-13 measurement in blood serum of men, non-pregnant and pregnant women. It was found that PP-13 level in pregnant women was significantly higher (225.8+/-100.5 pg/ml) than detected concentrations in non-pregnant women (17.1+/-45.9 pg/ml) or in men (6.8 +/- 13.1 pg/ml). Many samples from men and non-pregnant women showed zero level of PP-13. These results suggest

that PP-13 is a real placental protein and that two-antibody sandwich ELISA of PP-13 may be used as a screening tool in pregnant women.

References

1. Bohn. H., Winckler, W.. Grundmann. U.. Immunochemically detected placental proteins and their biological functions. *Arch. Gynecol. Obstet.*, **249**:107-118 (1991).

2. Rutanen, E.. Bohn, H., Seppala. M., Radioimmunoassay of placental protein 12: levels in amniotic fluid. cord blood. and serum of healthy adults. pregnant women and patients with trophoblastic disease. *Am. J. Obstet. Gynecol.*. **144**:460-463 (1982).

3. Howell, R.J.S.. Economides, D.. Teisner. B.. Farkas. A.G., Chard, T., Placental proteins 12 and 14 in pre-eclampsia, Acta. *Obstet. Gynecol., Scand.*, **68**:237-240 (1989).

4. Scherbakova, L.A.. Gocze, P.M.. Olefirenko, G.A., Than, G.N., Szabo, D.G., Petrunin, D.D.. Tatarinov. Yu. S., Csaba. I.F., Comparative study of enzyme-linked immunosorbent assay and radioimmunoassay techniques in determining serum placental protein 14 levels in gynecologic patients. *Tumor Biol.*. **12**:267-271 (1991).

5. Giulian, G.G., Moss R.L., and Greaser. M., Improved Methodology for Analysis and Quantitation of Proteins and one-dimensional silver-stained gel. Anal. Biochem.. **129**:277-287 (1983).

6. Eshhar, Z., Blatt, C., Bergman. Y., Haimovich. J., Induction of secretion of IgM from cells of the B cell line 38C-13 by somatic cell hybridization. *J. Immunol.*, **122**:2430-2434 (1979).

CLAIMS:

1. A monoclonal antibody (Mab) isolated using a two-Mab sandwich enzyme-linked immunosorbant assay (ELISA) and capable of binding Placental Protein 13 (PP-13).

2. A Mab according to Claim 1 produced by a hybridoma cell selected from the group consisting of clones # 26-2, 27-2-3, 215-28-3, 534-16 and 606-8-11-67.

3. A hybridoma clone selected from the group consisting of clones # 26-2, 27-2-3, 215-28-3, 534-16 and 606-8-11-67.

4. An immunoassay for measuring the level of PP-13 in a biological fluid comprising the steps of:

(a) bringing said fluid into contact with a Mab according to Claim 1, thereby forming Mab-PP-13 complexes;

(b) exposing said complexes to a second antibody linked to a signal-generating molecule, said second antibody being capable of binding said complexes, wherein said second antibody is also a Mab according to Claim 1; and

(c) providing conditions conducive to the production of a signal generated by said signal-generating molecule.

5. An immunoassay according to Claim 4 wherein said Mab in step (a) is bound to a solid phase.

6. An immunoassay according to Claim 4 wherein said signal generating molecule is an enzyme.

7. An immunoassay according to Claim 4 wherein said signal generating molecule is a ligand, and step (c) of claim 4 comprises incubating the product of step (b) with a ligand binding molecule linked to an enzyme.

8. An immunoassay according to Claim 7 wherein said ligand is biotin and said ligand-binding molecule is extravidin.

9. A kit for measuring the level of PP-13 in a biological fluid comprising

(a) a Mab according to Claim 1;

(b) a second antibody linked to a signal-generating molecule wherein said second antibody is also a Mab according to Claim 1; and

(c) PP-13 standard solutions.

10. A kit according to Claim 9 wherein said Mab in step (a) is bound to a solid phase.

11. A kit according to Claim 9 wherein said signal generating molecule is an enzyme.

12. A kit according to Claim 9 wherein said signal generating molecule is a ligand, and said kit further comprises a ligand binding molecule linked to an enzyme.

13. A kit according to Claim 12 wherein said ligand is biotin and said ligand-binding molecule is extravidin.

SDS-PAGE ELECTROPHORESIS OF MOUSE ANTI-PP-13 ASCITES & IgG



1. MW markers
2. Ascitic fluid #215-28-3
3. Purified IgG #215-28-3
4. Ascitic fluid #27-2-3
5. Purified IgG #27-2-3
6. Control (sample buffer)

Fig. 1


TESTING OF MOUSE ANTI-PP-13 SERUM IN DIRECT ELISA (1st bleeding)
ANTIBODY RESPONSE (OD)
2.5
2.25
2
1.75
1.5
1.25
1
0.75
0.5
0.25
0
1:200
1:600
1:1800
1:5400
1:16200
1:48600
SERUM DILUTION
Ab #1
Ab #2
Ab #3
Ab #4
Ab #5
NMS

Fig. 2


CLASSING OF ANTI-PP-13 ANTIBODIES
IN DIRECT ELISA (1st screening)
ANTIBODY RESPONSE (OD)
2.5
2.25
2
1.75
1.5
1.25
1
0.75
0.5
0.25
0
12
26
27
59
79
249
409
442
NMS
TISSUE CULTURE SUPERNATANT #
AP-Gt x mouse IgG
Biotin-Gt x mouse IgM

Fig. 3

TESTING OF ANTI-PP-13 ANTIBODIES IN SANDWICH ELISA (1st screening)



Fig. 4


Ab #79
Ab #215
Ab #249
Ab #409
Ab #442
ANTIBODY RESPONSE (OD)
2.5
2.25
2
1.75
1.5
1.25
1
0.75
0.5
0.25
0
0 0.05 0.1 0.2 0.5 1.0 2.0
PP-13, ng/ml

Fig. 4 (Cont.)

TESTING OF ANTI-PP-13 ANTIBODIES IN SANDWICH ELISA (cloning: 1st scrn)



Fig. 5


Ab #534
Ab #606
Ab #669
Ab #678
Ab #882
ANTIBODY RESPONSE (OD)
2
1.75
1.5
1.25
1
0.75
0.5
0.25
0
0 0.05 0.1 0.2 0.5 1.0
PP-13, ng/ml

Fig. 5 (Cont.)


CLASSING OF ANTI-PP-13 ANTIBODIES
IN DIRECT ELISA (cloning: 2nd scrn)
ANTIBODY RESPONSE (OD)
2.75
2.5
2.25
2
1.75
1.5
1.25
1
0.75
0.5
0.25
0
26-1
26-2
26-3
26-4
26-5
26-6
27-1
27-1-1
27-2-2
NMS
CLONE #
AP-Gt x mouse IgG
Biotin-Gt x mouse IgM

Fig. 6


CLASSING OF ANTI-PP-13 ANTIBODIES IN DIRECT ELISA (cloning: 2nd scrn)
ANTIBODY RESPONSE (OD)
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
27-2-3
27-2-5
27-2-9
27-2-10
27-2-12
27-2-14
27-3
27-4
27-5
NMS
CLONE #
AP-Gt x mouse IgG
Biotin-Gt x mouse IgM

Fig. 7


CLASSING OF ANTI-PP-13 ANTIBODIES IN DIRECT ELISA (cloning: 2nd scrn)
ANTIBODY RESPONSE (OD)
1.35
1.2
1.05
0.9
0.75
0.6
0.45
0.3
0.15
0
27-6
27-7
215-28
215-28-1
215-28-2
215-28-3
215-28-4
215-28-5
215-28-6
NMS
CLONE #
AP-Gt x mouse IgG
Biotin-Gt x mouse IgM

Fig. 8


CLASSING OF ANTI-PP-13 ANTIBODIES
IN DIRECT ELISA (cloning: 2nd scrn)
ANTIBODY RESPONSE (OD)
0.5
0.45
0.4
0.35
0.3
0.25
0.2
0.15
0.1
0.05
0
249
249-2
249-20
534-3
534-4
534-7
534-8
534-16
NMS
CLONE #
AP-Gt x mouse IgG
Biotin-Gt x mouse IgM

Fig. 9


CLASSING OF ANTI-PP-13 ANTIBODIES IN DIRECT ELISA (cloning: 3rd scrn)
ANTIBODY RESPONSE (OD)
2.25
2
1.75
1.5
1.25
1
0.75
0.5
0.25
0
249-20-13-4
249-20-13-5
249-20-13-6
534-16
606-4
606-8
606-8-11
NMS
CLONE #
AP-Gt x mouse IgG
Biotin-Gt x mouse IgM

Fig. 10

TWO-MONOCLONAL ANTIBODY SANDWICH ELISA IN DIFFERENT VARIANTS



Fig. 11


Ab/Biotin-Ab #27/534
ANTIBODY RESPONSE (OD)
2.5
2.25
2
1.75
1.5
1.25
1
0.75
0.5
0.25
0
0
0.05
0.1
0.2
0.5
1.0
PP-13, ng/ml


Ab/Biotin-Ab #27/606
ANTIBODY RESPONSE (OD)
2.5
2.25
2
1.75
1.5
1.25
1
0.75
0.5
0.25
0
0
0.05
0.1
0.2
0.5
1.0
PP-13, ng/ml

Fig. 11 (Cont.)


STANDARD CURVE OF PP-13 ELISA
(MONOCLONAL SANDWICH)
OD
2
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
0 50 100 150 200 250 300 350 400 450 500
PP-13 (pg/ml)
— 2SD Confidence limits

Fig. 12


SENSITIVITY OF PP-13 ELISA
(MONOCLONAL SANDWICH)
Sensitivity=10 pg/ml
OD
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0 10 20 30 40 50 60 70 80 90 100
PP-13 (pg/ml)
– 2SD Confidence limits

Fig. 13


DILUTION CURVE OF PP-13 IN BLOOD SERUM
(MONOCLONAL SANDWICH ELISA)
PP-13 pg/ml
300
270
240
210
180
150
120
90
60
30
0
1:2
1:4
1:8
1:16
0
0.125
0.25
0.375
0.5
0.625
0.75
0.875
1
Dilution scale
Standard PP-13 solution
Pooled blood serum

Fig. 14


ANALYTICAL RECOVERY TEST OF PP-13
(MONOCLONAL SANDWICH ELISA)
Estimated PP-13 level, pg/ml
225
200
175
150
125
100
75
50
25
0
0
25
50
75
100
125
150
175
200
Predetermined PP-13 level, pg/ml
PP-13 in control pool
PP-13 in pooled serum

Fig. 15

Combined Declaration for Patent Application and Power of Attorney

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; and that I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

ANTIBODIES TO PLACENTAL PROTEIN 13

the specification of which (check one)

[ ] is attached hereto;
[ ] was filed in the United States under 35 U.S.C. §111 on , as U.S. Appln. No. _____*; or
[X] was filed in the U.S. under 35 U.S.C. §371 by entry into the U.S. national stage of an international (PCT) application, PCT/IL00/00196; filed March 29, 2000, entry requested on October 1, 2001*; national stage application received U.S. Appln. No. _____*; §371/§102(e) date _____* (* if known)

and was amended on October 1, 2001 (if applicable).

(Include dates of amendments under PCT Art. 19 and 34 if PCT)

I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above; and I acknowledge the duty to disclose to the Patent and Trademark Office (PTO) all information known by me to be material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §§ 119 (a)-(d) and 365 (b) of any prior foreign application(s) for parent, inventor's or plant breeder's rights certificate(s), or under §365(a) of any PCT application which designated at least one country other than the U.S., listed below:

Application No.	Country	Filing Date (MM/DD/YYYY)
129273	Israel	March 30, 1999

If I claimed foreign priority above, I hereby identify below any foreign application for patent (including an international (PCT) application designating a country other than the United States) or for an inventor's or plant breeder's certificate, having a filing date before that of the earliest application from which foreign priority is claimed (if left blank, then there are none):

Non-Priority Application No.	Country	Filing Date (MM/DD/YYYY)

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional applications listed below:

Application No.	Filing Date (MM/DD/YYYY)

I hereby claim the benefit under 35 U.S.C. §120 of any prior U.S. non-provisional application(s) or under §365(c) of any prior PCT international application(s) designating the U.S., listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in such U.S. or PCT international application in the manner provided by the first paragraph of 35-U.S.C. §112, I acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Filing Date (MM/DD/YYYY)	Status (patented, pending, abandoned)
PCT/IL00/00196	March 29, 2000	Pending

As a named inventor, I hereby appoint the following registered practitioners to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

All of the practitioners associated with Customer Number 001444

Direct all correspondence to the address associated with **Customer Number 001444**, which is presently:

BROWDY AND NEIMARK, P.L.L.C.
624 Ninth Street, N.W.
Washington, D.C. 20001-5303
(202) 628-5197

Atty. Docket: PALTIELI-1

Title: ANTIBODIES TO PLACENTAL PROTEIN 13

U.S. Application filed October 1, 2001, Serial No. _____

PCT Application filed March 29, 2000, Serial No. PCT/IL00/00195

The undersigned hereby authorizes the U.S. Attorneys or Agents appointed herein to accept and follow instructions from Reinhold Cohn & Partners as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. Attorneys or Agents and the undersigned. In the event of a change of the persons from whom instructions may be taken, the U.S. Attorneys or Agents appointed herein will be so notified by the undersigned.

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF FIRST INVENTOR Yoav PALTIELI	INVENTOR'S SIGNATURE X	DATE X
RESIDENCE Haifa, Israel		CITIZENSHIP Israeli
POST OFFICE ADDRESS Einstein Street 75, 34602 Haifa, Israel		
FULL NAME OF SECOND JOINT INVENTOR Lev RABINOVITCH	INVENTOR'S SIGNATURE X	DATE X 28/10/01
RESIDENCE Kiryat Ata, Israel		CITIZENSHIP Israeli
POST OFFICE ADDRESS Rambam Street 2, 28000 Kiryat Ata, Israel		
FULL NAME OF THIRD JOINT INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENCE		CITIZENSHIP
POST OFFICE ADDRESS		
FULL NAME OF FOURTH JOINT INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENCE		CITIZENSHIP
POST OFFICE ADDRESS		
FULL NAME OF FIFTH JOINT INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENCE		CITIZENSHIP
POST OFFICE ADDRESS		
FULL NAME OF SIXTH JOINT INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENCE		CITIZENSHIP
POST OFFICE ADDRESS		

ALL INVENTORS MUST REVIEW APPLICATION AND DECLARATION BEFORE SIGNING. ALL ALTERATIONS MUST BE INITIALED AND DATED BY ALL INVENTORS PRIOR TO EXECUTION. NO ALTERATIONS CAN BE MADE AFTER THE DECLARATION IS SIGNED. ALL PAGES OF DECLARATION MUST BE SIGNED BY ALL INVENTORS.

Combined Declaration for Patent Application and Power of Attorney

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, and that I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

ANTIBODIES TO PLACENTAL PROTEIN 13

the specification of which (check one)

[ ] is attached hereto;
[ ] was filed in the United States under 35 U.S.C. §111 on , as U.S. Appln. No. _____*; or
[X] was filed in the U.S. under 35 U.S.C. §371 by entry into the U.S. national stage of an international (PCT) application, PCT/IL00/00196; filed March 29, 2000, entry requested on October 1, 2001*; national stage application received U.S. Appln. No. _____*; §371/§102(e) date _____* (* if known)

and was amended on October 1, 2001 (if applicable).
(Include dates of amendments under PCT Art. 19 and 34 if PCT)

I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above; and I acknowledge the duty to disclose to the Patent and Trademark Office (PTO) all information known by me to be material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §§ 119 (a)-(d) and 365 (b) of any prior foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or under §365(a) of any PCT application which designated at least one country other than the U.S., listed below:

Application No.	Country	Filing Date (MM/DD/YYYY)
129273	Israel	March 30, 1999

If I claimed foreign priority above, I hereby identify below any foreign application for patent (including an international (PCT) application designating a country other than the United States) or for an inventor's or plant breeder's certificate, having a filing date before that of the earliest application from which foreign priority is claimed (if left blank, then there are none):

Non-Priority Application No.	Country	Filing Date (MM/DD/YYYY)

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional applications listed below:

Application No.	Filing Date (MM/DD/YYYY)

I hereby claim the benefit under 35 U.S.C. §120 of any prior U.S. non-provisional application(s) or under §365(c) of any prior PCT international application(s) designating the U.S., listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in such U.S. or PCT international application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Filing Date (MM/DD/YYYY)	Status (patented, pending, abandoned)
PCT/IL00/00196	March 29, 2000	Pending

As a named inventor, I hereby appoint the following registered practitioners to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

All of the practitioners associated with Customer Number 001444

Direct all correspondence to the address associated with **Customer Number 001444**, which is presently:

BROWDY AND NEIMARK, P.L.L.C.
624 Ninth Street, N.W.
Washington, D.C. 20001-5303
(202) 628-5197

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF FIRST INVENTOR	INVENTOR'S SIGNATURE	DATE
Yoav PALTIELI	X Y. Paltieli	Oct 28, 2021
RESIDENCE		CITIZENSHIP
Haifa, Israel		Israeli
POST OFFICE ADDRESS		
Einstein Street 75, 34602 Haifa, Israel		
FULL NAME OF SECOND JOINT INVENTOR	INVENTOR'S SIGNATURE	DATE
Lev RABINOVITCH	X	X
RESIDENCE		CITIZENSHIP
Kiryat Ata, Israel		Israeli
POST OFFICE ADDRESS		
Remiyam Street 2, 28000 Kiryat Ata, Israel		
FULL NAME OF THIRD JOINT INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENCE		CITIZENSHIP
POST OFFICE ADDRESS		
FULL NAME OF FOURTH JOINT INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENCE		CITIZENSHIP
POST OFFICE ADDRESS		
FULL NAME OF FIFTH JOINT INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENCE		CITIZENSHIP
POST OFFICE ADDRESS		
FULL NAME OF SIXTH JOINT INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENCE		CITIZENSHIP
POST OFFICE ADDRESS		

ALL INVENTORS MUST REVIEW APPLICATION AND DECLARATION BEFORE SIGNING. ALL ALTERATIONS MUST BE INITIALED AND DATED BY ALL INVENTORS PRIOR TO EXECUTION. NO ALTERATIONS CAN BE MADE AFTER THE DECLARATION IS SIGNED. ALL PAGES OF DECLARATION MUST BE SIGNED BY ALL INVENTORS.